Summary The concentration of carcinoembryonic antigen (CEA), CA130, CA 125, SLX, CA 19-9, SPan 1, and tumour-associated glycoprotein 72 in the culture supernatant of 15 cancer cell lines and in the sera of 58 cancer patients was measured, and the co-expression of these antigens was examined by double determinant immunoradiometric assays. The high correlation coefficient of the concentrations and significant binding in the double determinant assays indicated a close relationship between CA125 and CA130 and between CA19-9 and SPanl. There was variable binding of the '25I-labelled anti-SLX, anti-CA19-9, and anti-SPanl antibodies to anti-CA130 beads that had been pre-incubated with the culture supernatants, suggesting the presence of the epitopes of SLX, CA19-9, and SPanl on the molecule expressing CA130. Similarly, the epitopes of SLX, CA19-9, and SPanl could be present on the molecule expressing CEA. '25I-labelled anti-CA19-9, anti-SLX, and anti-TAG-72 antibodies were bound in variable proportions to anti-CA130 beads or to anti-CEA beads that had been pre-incubated with patients' sera. However, CEA and CA130 were not expressed on the same molecule, either in the culture supernatant, or in patients' sera. In conclusion, the carbohydrate epitopes of CAI 9-9, SPan 1, SLX, and TAG-72 could be present on the molecule recognised by the anti-CA130 or anti-CEA antibody; however, the epitopes of CA130 and CEA did not co-exist on the same molecule.
The measurement of tumour-associated antigens in body fluids is useful for the diagnosis and monitoring of cancer patients (Sears et al., 1982; Bast et al., 1983; Sakahara et al., 1986) . Tumour-associated antigens recognised by different monoclonal antibodies are sometimes similar to each other and can be co-expressed on the same molecule (Hanisch et al., 1985; Lan et al., 1987; Yu et al., 1991) . We examined the similarity and co-expression of seven tumour markers, carcinoembryonic antigen (CEA), CA130, CA125, SLX, CAl9-9, SPanl, and tumour-associated glycoprotein 72 , in the culture supernatant of 15 cancer cell lines and in the sera of 58 cancer patients. Co-expression of the antigenic determinants, detected by commercially available monoclonal antibodies, was tested by double determinant immunoradiometric assay.
Materials and methods
Immunoradiometric assay Tumour markers were measured with commercially available kits, all of which are based on immunoradiometric assay using monoclonal antibodies. The kits contain an '251-labelled antibody and polystyrene beads that are coated with the same or another antibody.
The CEA and SPanl immunoradiometric assay kits were obtained from Dainabot (Tokyo, Japan). The immobilised anti-CEA antibody is a murine monoclonal antibody that recognises a peptide epitope common to CEA, nonspecific cross-reacting antigen (NCA), and NCA-2. The tracer anti-CEA antibody is a monoclonal antibody that recognises a peptide epitope present on both CEA and NCA-2, but not on NCA. The monoclonal antibody, SPanl, is coated on the beads and labelled with 1251 (Chung et al., 1987; Ho et al., 1988) . The antigen recognised by SPanl is also designated as SPanl. The CA125, CA19-9 and TAG-72 assay kits were obtained from Centocor (Malvern, PA, USA). In the CA125 assay, the monoclonal antibody, OC125, is used for both catcher and tracer (Bast et al., 1983; Klug et al., 1984) . The CA19-9 assay kit employs the monoclonal antibody 19-9, both as a catcher and as a tracer antibody (Sears et al., 1982; Del Villano et al., 1983) . The monoclonal antibody, CC49, is immobilised to beads and the monoclonal antibody, B72.3, is labelled with 1251I in the TAG-72 assay (Johnson et al., 1986; Muraro et al., 1988) . CA130 was measured with a kit that consisted of solid-phase 145-9 monoclonal antibody and 1251_ labelled 130-22 monoclonal antibody (Matsuoka et al., 1987; Kunimatsu et al., 1988; Saga et al., 1990) . The CA130 kit was supplied by Daiichi Radioisotope Laboratory (Tokyo, Japan). SLX, known as sialyl stage-specific embryonic antigen 1 (sialyl-SSEA-1), was measured using a kit provided by Otsuka Assay (Tokushima, Japan). The monoclonal antibody, FH-6, which recognises 2-3 sialyl Lex-i, was used for both catcher and tracer (Fukushi et al., 1984; Kannagi et al., 1986 These high correlations mean parallelism of the concentrations between CA125 and CA130 and between CA19-9 and SPanl. The binding of '25I-labelled anti-CA125 to anti-CA130 coated beads and 125I-labelled anti-SPanl to anti-CA19-9 coated beads that had been pre-incubated with supernatants is shown in Table II (Kiyozuka, 1987; Ishiwata et al., 1987; Sakamoto, 1988 The concentrations of tumour markers in the culture supernatant of cell lines are shown in Table I . The correlation coefficients for CA125 and CA130 levels and for CA19-9 and SPanl antigen levels were 0.981 and 0.940, respectively. anti-SPanl to anti-CA19-9 coated beads was also correlated with both CA19-9 and SPanl antigen values, suggesting coexpression of 19-9 and SPanl epitopes on the same molecule. Figure 1 shows the results of double determinant assays of the culture supernatants using anti-CA130 antibody as a catcher. Anti-SLX, anti-CA19-9, and anti-SPanl antibodies bound anti-CA130 beads variably. This suggests that the antigenic determinants of SLX, CA19-9, and SPanl were (Figure 2 ). There was no binding of anti-CEA tracer to the anti-CA 130 beads or of anti-CA 130 tracer to the anti-CEA beads.
The culture supernatant of the SW 1116 cell line was subjected to Sephacryl S300 gel chromatography and each fraction was assayed (Figure 3) . CEA was detected at fraction number 50, corresponding to a molecular weight of 180-200kD. CA19-9, SPanl, SLX, and CA130 were detected at the void volume of fraction number 40, corresponding to a molecular weight of more than 1OOOkD. The binding of anti-CEA, anti-CA19-9, anti-SPanl, anti-SLX, and anti-CA130 tracers to anti-CA130 beads and anti-CEA beads in fractions 40 and 50 is shown in Figures 4 and 5 . The antigenic determinants of CA19-9, SPanl, and SLX were present in the same fraction (more than 1000 kD) recognised by the anti-CA130 antibody (Figure 4) . The anti-CA19-9, anti-SPanl, and anti-SLX antibodies bound anti-CEA beads in fraction 40, suggesting that large molecules of more than 1OOOkD express both CEA and the epitopes of CA19-9, SPanl, and SLX ( Figure 5 ). Epitopes of CA19-9 and SPanl were also present on the 180kD CEA molecule in fraction 50. There was no binding of the anti-CA130 tracer to the anti-CEA beads or of the anti-CEA tracer to the anti-CA130 beads in either fraction 40 or fraction 50.
The concentration of tumour markers in patients' sera is shown in Table III . The correlation coefficient for CA19-9 and SPan1 antigen was very high (r = 0.942), as it was in the culture supernatant. The correlation coefficient for CA130 and CA125 was also high (r = 0.973). The anti-CA19-9, anti-SLX, and anti-TAG-72 bound variably to both anti-CA130 and anti-CEA beads that had been pre-incubated with patients' sera (Figures 6 and 7, Table IV ).
Discussion
The good correlation of CA130 and CA125 concentrations, together with the finding that '251-labelled anti-CA125 bound to anti-CA130 coated beads that had been pre-incubated with culture supernatant, suggests that anti-CA125 and anti-CA130 recognise the same molecule. However, because anti-CA130 antibodies do not compete with anti-CA125 antibody for the CA125 epitope in the immunoradiometric assay, the epitope of CA130 is different from that of CA125 (Matsuoka et al., 1987; Kunimatsu et al., 1988; Saga et al., 1990) . good coincidence in most patients (Saga et al., 1990) , we have found high CA125 and normal CA130 levels in the sera of five patients in a series of more than 8000 samples (Hosono et al., 1992) . We did not find any malignant diseases in any of these five patients. Measurement of circulating CA130 may resolve the problems of CA125 false-positive cases.
Spanl antigen and CA19-9 were also found to be coexpressed on the same molecule. While anti-CA19-9 antibody competes with anti-SPanl antibody for the SPanl epitope (Ho et al., 1988) , anti-CA19-9 does not react with colonic cancer tissues from patients with Lewisa, Lewisb negative phenotype, although anti-SPanl does (Chung et al., 1987) . SPanl would be a better tumour marker in patients with Lewisa'b-phenotype.
The epitopes of CA19-9, SPanl, SLX, and TAG-72 are carbohydrates with sialic acid (Ho et al., 1988; Fukushi et al., 1984; Magnani et al., 1982; Kjeldsen et al., 1988) . Although the epitopes of CA125 and CA130 have not yet been fully determined, the antigen defined by anti-CA125 and anti-CA130 antibodies has been shown to be a heat-labile large molecular weight glycoprotein (Matsuoka et al., 1987; Masuho et al., 1984; Davis et al., 1986) . The co-expression of tumour-associated carbohydrate epitopes has been suggested I::: co so0 50 40 on large molecular weight mucin; CA125 and CAl9-9 have been found to be present on a mucin glycoprotein from human milk (Hanisch et al., 1985) . Epitopes of CA19-9 and DU-PAN-2 may be co-expressed on the same mucin molecule in varying proportions (Lan et al., 1987) . A fraction of ascites fluids from different ovarian cancer patients was 2.1 2/58 1.2 7/58 aIn each double determinant assay the mean plus two standard deviations of the bound % in the group of patients whose serum concentrations of one or both of the corresponding determinants were negative was set as a cut-offvalue. The cut-off value ofeach determinant was shown in Table III. shown to contain moieties which bound to anti-CA125 antibody on a solid phase immunoadsorbent and which also bound the '25I-labelled anti-CA19-9, anti-TAG-72, anti-DF3, or anti-CA3632 monoclonal antibodies in a double determinant immunoradiometric assay (Yu et al., 1991) . The present study demonstrated that epitopes of CA19-9, SPanl, SLX and TAG-72 could be present on the molecule expressing the epitope of CA130.
An interesting finding was the presence of the epitopes of CA19-9, SPanl, SLX and TAG-72 on the molecule expressing CEA. Since the solid-phase monoclonal antibody in the CEA kit recognises a peptide epitope common to CEA, NCA, and NCA-2, the molecules caught by the anti-CEA beads may thus be not only CEA, but also NCA or NCA-2. The molecular weight of CEA or CEA-associated antigens is less than 180 kD. The molecules recognised by anti-CA 19-9, anti-SPanl, anti-SLX, and anti-TAG-72 antibodies have been reported to be large molecular weight glycoproteins ranging from 200 kD to over 5000 kD (Lan et al., 1987; Johnson et al., 1986; Kannagi et al., 1986; Magnani et al., 1983) . In this study, we found molecules expressing both CEA and sialylated carbohydrate epitopes to be distributed both in void volume fraction and in the fraction corresponding to a molecular weight of 180 kD after fractionation of the SWI 116 culture supernatant on Sephacryl S300. It is possible that the large molecular weight species may be a glycoprotein complex containing both CEA and the carbohydrate epitopes; further characterisation is thus required. In any case, the molecule recognised by the anti-CEA antibody could have CA19-9, SPanl, SLX, or TAG-72 epitopes.
The epitope of CA130 has not yet been clearly demonstrated; however it is considered to be composed of, at least in part, conformationally dependent peptide (Matsuoka et al., 1987) . The peptide epitope of CEA and the peptiderelated epitope of CA 130 were not present on the same molecule.
The present study revealed that some of the tumour-associated epitopes were co-expressed on the same molecule. This would be true for other monoclonal antibodies recognising tumour-associated antigen. There are three cases in the similarity and co-expression. First, two antibodies recognize almost the same epitope, such as CA19-9 and SPanl. Secondary, two different epitopes are consistently co-expressed on the same molecule, such as CA125 and CA130. Finally, an epitope is expressed in varying proportions on the molecule bearing another epitope, such as several carbohydrate epitopes on CEA or CA130 molecule.
Although we did not examine the sensitivity or specificity of the newly developed double determinant assay extensively, it may be possible to obtain better assay systems with greater sensitivity and specificity by using new combinations of monoclonal antibodies. Indeed, improvement of assay sensitivity has already been shown in a heterologous assay using anti-CA125 and anti-CA130 antibodies (Kunimatsu et al., 1988) .
